Thorpy Michael J, Schwartz Jonathan R L, Kovacevic-Ristanovic Ruzica, Hayduk Roza
Sleep-Wake Disorders Center, Montefiore Hospital, 111 East 210th Street, Bronx, NY 10467, USA
Psychopharmacology (Berl). 2003 Jun;167(4):380-5. doi: 10.1007/s00213-002-1343-4. Epub 2003 Apr 23.
Modafinil is a first-line wake-promoting medication and a useful therapeutic alternative to psychostimulant medications for excessive daytime sleepiness.
This 5-week, randomized, open-label study evaluated three strategies for switching patients from methylphenidate, a commonly used psychostimulant, to modafinil.
Patients ( n=40) with excessive daytime sleepiness related to narcolepsy, who had received previous treatment with methylphenidate, were switched from methylphenidate to modafinil (200 mg/day followed by 400 mg/day) without a washout period between treatments, with a 2-day washout period between treatments, or by using a taper-down/titrate-up protocol. Adverse events were recorded throughout the study, and Epworth Sleepiness Scale scores were determined at the end of the study.
The majority of patients (95%) were successfully switched to modafinil. At the study end point, mean Epworth Sleepiness Scale scores were <12 for each treatment group. All three switching strategies were well tolerated, with adverse events mild or moderate in nature. Adverse events most frequently reported during modafinil treatment were among those seen previously in large-scale, placebo-controlled studies. There were no meaningful differences among the treatment groups in the frequency or severity of adverse events or in their relationship to modafinil treatment. Only one patient discontinued modafinil treatment because of a treatment-related adverse event (i.e. moderate headache); another patient discontinued due to insufficient efficacy.
Switching from methylphenidate to modafinil was well tolerated with or without a washout period or when the methylphenidate dose is gradually tapered during initiation of modafinil therapy. Daytime wakefulness was maintained in patients who have switched from methylphenidate to modafinil. These data suggest that patients with narcolepsy may be switched from methylphenidate to modafinil with few complications and inconveniences.
莫达非尼是一种一线促醒药物,是治疗白天过度嗜睡的精神兴奋药物的一种有用的治疗替代药物。
这项为期5周的随机开放标签研究评估了三种将患者从常用精神兴奋药物哌甲酯转换为莫达非尼的策略。
40例与发作性睡病相关的白天过度嗜睡且曾接受哌甲酯治疗的患者,在治疗期间不设洗脱期、设2天洗脱期或采用递减/递增方案从哌甲酯转换为莫达非尼(初始剂量200mg/天,随后400mg/天)。在整个研究过程中记录不良事件,并在研究结束时测定爱泼沃斯思睡量表评分。
大多数患者(95%)成功转换为莫达非尼。在研究终点,每个治疗组的平均爱泼沃斯思睡量表评分均<12。所有三种转换策略耐受性良好,不良事件性质为轻度或中度。莫达非尼治疗期间最常报告的不良事件是之前在大规模安慰剂对照研究中出现过的。治疗组之间在不良事件的频率或严重程度或其与莫达非尼治疗的关系方面没有有意义的差异。只有1例患者因与治疗相关的不良事件(即中度头痛)停用莫达非尼治疗;另1例患者因疗效不佳而停药。
无论有无洗脱期,或在莫达非尼治疗开始时逐渐减少哌甲酯剂量,从哌甲酯转换为莫达非尼均耐受性良好。从哌甲酯转换为莫达非尼的患者白天保持清醒。这些数据表明,发作性睡病患者从哌甲酯转换为莫达非尼时可能很少出现并发症和不便。